Orthopedics Articles

Orthopedics

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lewiecki EM et al. – Denosumab suppresses bone turnover by inhibiting the action of RANKL on osteoclasts. Denosumab reduces bone turnover and increases bone mineral density in postmenopausal women with low bone mineral density, reduces fracture risk in women with postmenopausal osteoporosis, and inhibits structural damage in patients with rheumatoid arthritis when added to ongoing methotrexate treatment. It is generally well tolerated, with a good safety profile. Adverse and serious adverse events, including infections and malignancy, are similar in patients treated with denosumab or placebo.

Related Articles

Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The Journal of Urology, 11/16/09    Relevance Score: 87%

A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09    Relevance Score: 83%

Bone health and prostate cancer
Prostate Cancer & Prostatic Diseases, 11/13/09    Relevance Score: 77%

Today in Bone Metabolism...keeping you current

Pattern of Bone Mineral Density in Sickle Cell Disease Patients with the High-Hb F Phenotype
Acta Haematologica, 12/04/09

Monitoring osteoporosis treatment
Best Practice & Research: Clinical Rheumatology, 12/04/09

Three-dimensional osseous micro-architecture of the distal humerus: Implications for internal fixation of osteoporotic fracture
Journal of Shoulder and Elbow Surgery, 12/04/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address